Staar Surgical Co (STAA) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Staar Surgical Co (STAA) stock forecast summary
On Oct. 13, 2026, STAA is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Staar Surgical Co is a small-cap company with a market capitalization of $1.10B. It ranks number 6 by market capitalization among the 8 Ophthalmic Goods issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for STAA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, STAA included.
Follow STAA freeSTAA price chart and AI forecast
How STAA ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Staar Surgical Co (STAA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Ophthalmic Goods peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | STAA | Rank |
|---|---|---|
| Market Cap | $1.10B | 6/8 |
| P/B Ratio | 3.02x | 2/7 |
| EPS | $-0.02 | – |
| Book Value/Share | $7.29 | – |
| Revenue/Share | $6.77 | – |
| FCF/Share | $-0.13 | – |
Profitability & Margins
| Metric | STAA | Rank |
|---|---|---|
| ROIC | 3.4% | 3/6 |
| Gross Margin | 76.6% | 2/6 |
| Operating Margin | 4.0% | 4/6 |
| EBT Margin | 5.1% | 2/6 |
| Tax Rate | 77.9% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | STAA | Rank |
|---|---|---|
| Current Ratio | 4.66x | 2/7 |
| Quick Ratio | 4.24x | 2/7 |
| D/E Ratio | 0.30x | 6/7 |
| Financial Leverage | 1.30x | 6/7 |
| Working Capital | $269M | 3/7 |
Cash Flow
| Metric | STAA | Rank |
|---|---|---|
| Operating Cash Flow | -$3M | 6/8 |
| Free Cash Flow | -$7M | 5/6 |
| Capital Spending | -$4M | 1/6 |
| FCF/Sales | -2.0% | 5/6 |
| CapEx/Sales | 1.0% | 6/6 |
Operational Efficiency
| Metric | STAA | Rank |
|---|---|---|
| Asset Turnover | 0.71x | 3/7 |
| Receivables Turnover | 3.5x | 7/7 |
| Inventory Turnover | 2.5x | 3/6 |
| Fixed Assets Turnover | 4.9x | 4/7 |
| Days Sales Outstanding | 106 days | 1/7 |
| Days Inventory | 143 days | 4/6 |
| Payables Period | 62 days | 3/5 |
| Cash Conversion Cycle | 187 days | 3/5 |
Income Statement
| Metric | STAA | Rank |
|---|---|---|
| Total Revenue | $339M | 5/7 |
| Operating Income | $13M | 5/7 |
| R&D Expense | $36M | 5/6 |
| SG&A Expense | $246M | 5/7 |
| Cost of Goods Sold | $79M | 5/7 |
Dividend & Shareholder Information
| Metric | STAA | Rank |
|---|---|---|
| Shares Outstanding | 50M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $342M | 72.0% of assets |
| Cash & Short-term Investments | $149M | 31.3% of assets |
| Accounts Receivable | $98M | 20.7% of assets |
| Inventory | $31M | 6.6% of assets |
| Total Liabilities | $110M | 23.1% of assets |
| Short-term Debt | $60M | 12.6% of assets |
STAA quarterly financials and insider trading
Staar Surgical Co (STAA) industry peers
Companies classified under the same SEC industry code as Staar Surgical Co (Ophthalmic Goods): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| STAA Staar Surgical Co | ▶ | $1.10B |
| ALC Alcon Inc | ▼ | $30.71B |
| COO Cooper Companies, Inc. | ▼ | $10.38B |
| BLCO Bausch & Lomb Corp | ▶ | $5.65B |
| WRBY Warby Parker Inc. | ▲ | $3.21B |
| EYE National Vision Holdings, Inc. | ▼ | $1.35B |
| RXST Rxsight, Inc. | ▲ | $188M |
| LUCY Innovative Eyewear Inc | ▲ | $8M |
Where STAA sits on the market map
Staar Surgical Co (STAA) stock news
Loading...
Staar Surgical Co (STAA) stock forecast FAQ
What is the Staar Surgical Co (STAA) stock forecast?
On Oct. 13, 2026, STAA is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Staar Surgical Co stock predictions?
A per-ticker accuracy statistic for STAA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Staar Surgical Co forecasts updated?
Staar Surgical Co forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Staar Surgical Co's industry peers?
8 issuers in our coverage, STAA included, share the SEC industry code Ophthalmic Goods. The largest are: Alcon Inc (ALC), Cooper Companies, Inc. (COO), Bausch & Lomb Corp (BLCO), Warby Parker Inc. (WRBY), National Vision Holdings, Inc. (EYE), Rxsight, Inc. (RXST).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.